A Peek At What Vascular Biogenics Ltd. (VBLT) Insiders Are Doing

SNOW Stock
SNOW Stock

Vascular Biogenics Ltd. (NASDAQ:VBLT) saw an upside of 4.04% to close Tuesday at $0.16 after adding $0.01 on the day. The 5-day average trading volume is 1,397,580 shares of the company’s common stock. It has gained $0.1649 in the past week and touched a new high 3 times within the past 5 days. An average of 1,270,285 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,482,604.

VBLT’s 1-month performance is 43.90% or $0.0460 on its low of $0.1065 reached on 12/28/22. The company’s shares have touched a 52-week low of $0.10 and high of $2.20, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, VBLT has achieved 30.83% or $0.0370 and has reached a new high 5 times. However, the current price is down -92.86% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

VBLT stock has a beta of 0.75. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.75 while the price-to-book (PB) in the most recent quarter is 0.48.

Vascular Biogenics Ltd.’s quick ratio for the period ended June 29 was 2.80, with the current ratio over the same period at 2.80.. In terms of profitability, the gross margin trailing 12 months is 71.10%. The firm’s gross profit as reported stood at $0.4 million against revenue of $0.77 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Vascular Biogenics Ltd.’s cash and short-term investments amounted to $31.16 million against total debt of $1.85 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 19.02% to $29.92 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected VBLT to announce -$0.1 per share in earnings in its latest quarter, but it posted -$0.12, representing a -20.00% surprise. EBITDA for the quarter stood at more than -$8.91 million. VBLT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 10.22 million, with total debt at $1.85 million.

Let’s look briefly at Vascular Biogenics Ltd. (VBLT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 62.69% to suggest the stock is trending Neutral, with historical volatility in this time period at 74.82%.

The stock’s 5-day moving average is $0.1507, reflecting a +6.08% or $0.0090 change from its current price. VBLT is currently trading +36.52% above its 20-day SMA, -29.69% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +36.76% and SMA200 by-91.23%.

Stochastic %K and %D was 83.28% and 79.37% and the average true range (ATR) pointed at 0.0140. The RSI (14) points at 60.22%, while the 14-day stochastic is at 78.88% with the period’s ATR at 0.0140. The stock’s 9-day MACD Oscillator is pointing at 0.0074 and 0.0074 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Vascular Biogenics Ltd. (NASDAQ: VBLT), Oppenheimer downgraded it to a Perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for VBLT stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate VBLT as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is VBLT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $5.00 and a high of $5.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for Vascular Biogenics Ltd. (VBLT) stock is $5.00.


Please enter your comment!
Please enter your name here